Lilly's Lechleiter sees pharma clouds abroad

Eli Lilly ($LLY) CEO John Lechleiter (photo) says price squeezes in Europe and Japan will be key challenges to his company's sales in 2012, one week after the company predicted a bigger-than-expected decline in profits this year. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.